Xuefeng Huang

Oct 9, 2024 | bmccancer.biomedcentral.com | Cheng Cai |Xia Zhang |Xiaonan Sun |Li Chen |Jianping Wang |Xuefeng Huang | +9 more

The study is an open-label, single-arm, multicentre, prospective phase II trial. MSS/pMMR LARC Patients will receive node-sparing modified short-course radiotherapy (25 Gy/5f). The irradiated planned target volume will only include the primary tumour bed but not the tumour-draining lymph nodes, followed by 3 cycles of capecitabine plus oxaliplatin (CAPOX) chemotherapy and tislelizumab. Then, patients will undergo TME. The pCR rate, adverse effects, and long-term prognosis will be analysed.